Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
A qualitative study of chronic pain and opioid use: The impact of restrictive prescribing
CONCLUSIONS: Opioid use for CP is complex and multifaceted. The continuum of pain and opioid use disorder can begin with a prescription for acute pain and continue for the treatment of CP. Patients described how continued opioid use was not to "get high" but for pain control to improve their quality of life, continue to work, and be productive. For those who experience physical dependence on opioids, access to treatment is vital to recovery and pain management.KEY MESSAGE: Without individualized managed care, people confronted with a sudden interruption in prescription opioids may turn to illicit drugs to mitigate symptoms...
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Cara L Sedney Patricia Dekeseredy Marissa Davis Treah Haggerty Source Type: research
Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
A qualitative study of chronic pain and opioid use: The impact of restrictive prescribing
CONCLUSIONS: Opioid use for CP is complex and multifaceted. The continuum of pain and opioid use disorder can begin with a prescription for acute pain and continue for the treatment of CP. Patients described how continued opioid use was not to "get high" but for pain control to improve their quality of life, continue to work, and be productive. For those who experience physical dependence on opioids, access to treatment is vital to recovery and pain management.KEY MESSAGE: Without individualized managed care, people confronted with a sudden interruption in prescription opioids may turn to illicit drugs to mitigate symptoms...
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Cara L Sedney Patricia Dekeseredy Marissa Davis Treah Haggerty Source Type: research
Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
A qualitative study of chronic pain and opioid use: The impact of restrictive prescribing
CONCLUSIONS: Opioid use for CP is complex and multifaceted. The continuum of pain and opioid use disorder can begin with a prescription for acute pain and continue for the treatment of CP. Patients described how continued opioid use was not to "get high" but for pain control to improve their quality of life, continue to work, and be productive. For those who experience physical dependence on opioids, access to treatment is vital to recovery and pain management.KEY MESSAGE: Without individualized managed care, people confronted with a sudden interruption in prescription opioids may turn to illicit drugs to mitigate symptoms...
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Cara L Sedney Patricia Dekeseredy Marissa Davis Treah Haggerty Source Type: research
Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
A qualitative study of chronic pain and opioid use: The impact of restrictive prescribing
CONCLUSIONS: Opioid use for CP is complex and multifaceted. The continuum of pain and opioid use disorder can begin with a prescription for acute pain and continue for the treatment of CP. Patients described how continued opioid use was not to "get high" but for pain control to improve their quality of life, continue to work, and be productive. For those who experience physical dependence on opioids, access to treatment is vital to recovery and pain management.KEY MESSAGE: Without individualized managed care, people confronted with a sudden interruption in prescription opioids may turn to illicit drugs to mitigate symptoms...
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Cara L Sedney Patricia Dekeseredy Marissa Davis Treah Haggerty Source Type: research
Legislative and regulatory barriers to pharmacies dispensing buprenorphine for OUD
CONCLUSION: Severe, intolerable reactions/side effects from the naloxone component of BNx are not uncommon, but legislative and regulatory restrictions on the mono-product prohibit providers and pharmacies in some states from prescribing and dispensing BUP. The participants in this qualitative study found it necessary to travel significant distances to obtain their prescribed medication, thereby potentially limiting access to this life-saving therapy.PMID:37879668 | DOI:10.5055/jom.2023.0807 (Source: Journal of Opioid Management)
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Daniel M Strickland Jordon T Baker Source Type: research
A qualitative study of chronic pain and opioid use: The impact of restrictive prescribing
CONCLUSIONS: Opioid use for CP is complex and multifaceted. The continuum of pain and opioid use disorder can begin with a prescription for acute pain and continue for the treatment of CP. Patients described how continued opioid use was not to "get high" but for pain control to improve their quality of life, continue to work, and be productive. For those who experience physical dependence on opioids, access to treatment is vital to recovery and pain management.KEY MESSAGE: Without individualized managed care, people confronted with a sudden interruption in prescription opioids may turn to illicit drugs to mitigate symptoms...
Source: Journal of Opioid Management - October 25, 2023 Category: Addiction Authors: Cara L Sedney Patricia Dekeseredy Marissa Davis Treah Haggerty Source Type: research
Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study
Recent policies have lessened restrictions around prescribing buprenorphine-naloxone (buprenorphine) for the treatment of opioid use disorder (OUD). The primary concern expressed by critics of these policies i... (Source: Harm Reduction Journal)
Source: Harm Reduction Journal - October 17, 2023 Category: Drugs & Pharmacology Authors: Jo ëlla W. Adams, Michael Duprey, Sazid Khan, Jessica Cance, Donald P. Rice and Georgiy Bobashev Tags: Research Source Type: research
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
CONCLUSIONS: Baseline anxiety severity did not significantly impact retention in OAT for adults with POUD, and there was no significant effect modification by OAT type. However, the overall retention rates were low, highlighting the need to develop new strategies to minimize the risk of attrition from treatment.CLINICAL TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov (NCT03033732).PMID:37697811 | DOI:10.1177/07067437231194385 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - September 12, 2023 Category: Psychiatry Authors: Anees Bahji Gabriel Bastien Paxton Bach JinCheol Choi Bernard Le Foll Ron Lim Didier Jutras-Aswad M Eugenia Socias Source Type: research
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
CONCLUSIONS: Baseline anxiety severity did not significantly impact retention in OAT for adults with POUD, and there was no significant effect modification by OAT type. However, the overall retention rates were low, highlighting the need to develop new strategies to minimize the risk of attrition from treatment.CLINICAL TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov (NCT03033732).PMID:37697811 | DOI:10.1177/07067437231194385 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - September 12, 2023 Category: Psychiatry Authors: Anees Bahji Gabriel Bastien Paxton Bach JinCheol Choi Bernard Le Foll Ron Lim Didier Jutras-Aswad M Eugenia Socias Source Type: research
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
CONCLUSIONS: Baseline anxiety severity did not significantly impact retention in OAT for adults with POUD, and there was no significant effect modification by OAT type. However, the overall retention rates were low, highlighting the need to develop new strategies to minimize the risk of attrition from treatment.CLINICAL TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov (NCT03033732).PMID:37697811 | DOI:10.1177/07067437231194385 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - September 12, 2023 Category: Psychiatry Authors: Anees Bahji Gabriel Bastien Paxton Bach JinCheol Choi Bernard Le Foll Ron Lim Didier Jutras-Aswad M Eugenia Socias Source Type: research
The Association Between Self-Reported Anxiety and Retention in Opioid Agonist Therapy: Findings From a Canadian Pragmatic Trial
CONCLUSIONS: Baseline anxiety severity did not significantly impact retention in OAT for adults with POUD, and there was no significant effect modification by OAT type. However, the overall retention rates were low, highlighting the need to develop new strategies to minimize the risk of attrition from treatment.CLINICAL TRIAL REGISTRATION: This study was registered in ClinicalTrials.gov (NCT03033732).PMID:37697811 | DOI:10.1177/07067437231194385 (Source: Canadian Journal of Psychiatry)
Source: Canadian Journal of Psychiatry - September 12, 2023 Category: Psychiatry Authors: Anees Bahji Gabriel Bastien Paxton Bach JinCheol Choi Bernard Le Foll Ron Lim Didier Jutras-Aswad M Eugenia Socias Source Type: research
